| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa.
|
Anesth Analg
|
2007
|
2.12
|
|
2
|
Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding.
|
Anesth Analg
|
2011
|
1.77
|
|
3
|
The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations.
|
Anesth Analg
|
2010
|
1.48
|
|
4
|
Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro.
|
Thromb Res
|
2004
|
1.42
|
|
5
|
A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery.
|
Transfusion
|
2011
|
1.07
|
|
6
|
The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography.
|
Anesth Analg
|
2005
|
1.03
|
|
7
|
Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.
|
Thromb Res
|
2007
|
1.02
|
|
8
|
Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion.
|
Transfusion
|
2013
|
0.96
|
|
9
|
The effects of argatroban on thrombin generation and hemostatic activation in vitro.
|
Anesth Analg
|
2004
|
0.95
|
|
10
|
Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P).
|
Anesth Analg
|
2008
|
0.91
|
|
11
|
A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass.
|
Anesth Analg
|
2008
|
0.87
|
|
12
|
Clinical measures of heparin's effect and thrombin inhibitor levels in pediatric patients with congenital heart disease.
|
Anesth Analg
|
2006
|
0.86
|
|
13
|
Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study.
|
Anesthesiology
|
2002
|
0.83
|
|
14
|
The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry.
|
Anesth Analg
|
2012
|
0.83
|
|
15
|
An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates.
|
Anesth Analg
|
2005
|
0.82
|
|
16
|
Ensembles of uncertain mathematical models can identify network response to therapeutic interventions.
|
Mol Biosyst
|
2010
|
0.82
|
|
17
|
In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma.
|
J Cardiothorac Vasc Anesth
|
2009
|
0.82
|
|
18
|
Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors.
|
Blood Coagul Fibrinolysis
|
2007
|
0.80
|
|
19
|
A comparative study of prothrombin complex concentrates and fresh-frozen plasma for warfarin reversal under static and flow conditions.
|
Thromb Haemost
|
2011
|
0.80
|
|
20
|
The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation.
|
Br J Haematol
|
2006
|
0.80
|
|
21
|
Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin.
|
Anesth Analg
|
2007
|
0.79
|
|
22
|
Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice.
|
Thromb Haemost
|
2010
|
0.78
|
|
23
|
Development of a fast and simple liquid chromatography-tandem mass spectrometry method for the quantitation of argatroban in patient plasma samples.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2012
|
0.78
|
|
24
|
Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding.
|
Platelets
|
2004
|
0.78
|
|
25
|
Isoflurane induces dopamine transporter trafficking into the cell cytoplasm.
|
Synapse
|
2004
|
0.78
|
|
26
|
The influence of red wine or white wine intake on platelet function and viscoelastic property of blood in volunteers.
|
Platelets
|
2004
|
0.78
|
|
27
|
Plasma and cerebral spinal fluid tranexamic acid quantitation in cardiopulmonary bypass patients.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2011
|
0.78
|
|
28
|
Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII.
|
Blood Coagul Fibrinolysis
|
2008
|
0.78
|
|
29
|
Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass.
|
Anesth Analg
|
2008
|
0.77
|
|
30
|
A novel method to assess platelet inhibition by eptifibatide with thrombelastograph.
|
Anesth Analg
|
2004
|
0.77
|
|
31
|
Tissue plasminogen activator and thrombin generation measurements using the Thrombinoscope.
|
Blood Coagul Fibrinolysis
|
2006
|
0.76
|
|
32
|
Interaction between thrombin mutant W215A/E217A and direct thrombin inhibitor.
|
Blood Coagul Fibrinolysis
|
2008
|
0.76
|
|
33
|
In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
|
Thromb Haemost
|
2009
|
0.76
|
|
34
|
Quantitative assessment of fibrinogen cross-linking by epsilon aminocaproic acid in patients with end-stage liver disease.
|
Liver Transpl
|
2004
|
0.75
|
|
35
|
Argatroban "reversal" is caused by nonphysiologic stimulation of coagulation, not activated factor VII.
|
J Cardiothorac Vasc Anesth
|
2010
|
0.75
|
|
36
|
The vasodilatory effects of hydralazine, nicardipine, nitroglycerin, and fenoldopam in the human umbilical artery.
|
Anesth Analg
|
2003
|
0.75
|
|
37
|
A Step Toward Balance: Thrombin Generation Improvement via Procoagulant Factor and Antithrombin Supplementation.
|
Anesth Analg
|
2016
|
0.75
|
|
38
|
Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan.
|
Thromb Haemost
|
2005
|
0.75
|
|
39
|
Effects of a plasma-derived C1 esterase inhibitor on hemostatic activation, clot formation, and thrombin generation.
|
Blood Coagul Fibrinolysis
|
2014
|
0.75
|
|
40
|
In Response.
|
Anesth Analg
|
2017
|
0.75
|
|
41
|
Optimizing Thrombin Generation with 4-Factor Prothrombin Complex Concentrates in Neonatal Plasma After Cardiopulmonary Bypass.
|
Anesth Analg
|
2016
|
0.75
|
|
42
|
Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.
|
Blood Coagul Fibrinolysis
|
2008
|
0.75
|
|
43
|
In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel.
|
Thromb Res
|
2013
|
0.75
|
|
44
|
Prophylactic use of factor IX concentrate in a Jehovah's Witness patient.
|
Ann Thorac Surg
|
2009
|
0.75
|
|
45
|
In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition.
|
Thromb Haemost
|
2010
|
0.75
|
|
46
|
The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
|
Anesth Analg
|
2012
|
0.75
|
|
47
|
Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin.
|
Anesthesiology
|
2008
|
0.75
|
|
48
|
In Response.
|
Anesth Analg
|
2017
|
0.75
|